SGLT2i: Diabetes & Heart Failure

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are novel anti-diabetic drugs that lowers blood glucose. This feed focuses on the role of SGLT2i in diabetes and reducing heart failure.

September 15, 2020
Open Access

Euglycemic Diabetic Ketoacidosis Precipitated by SGLT-2 Inhibitor Use, Pericarditis, and Fasting: A Case Report

Clinical Practice and Cases in Emergency Medicine
Rebecca A MendelsohnLisa M Clayton
September 21, 2020
Comment / Editorial
Open Access

Does acute treatment of dapagliflozin reduce cardiac infarct size through direct cardiac effects or reductions in blood glucose levels?

Cardiovascular Diabetology
Coert J Zuurbier
September 16, 2020

Dapagliflozin Improves Left Ventricular Myocardial Longitudinal Function in Patients With Type 2 Diabetes

JACC. Cardiovascular Imaging
Alexander BrownChim C Lang
September 19, 2020

Obesity COVID-19 patients show more severe pneumonia lesions on CT chest imaging

Diabetes, Obesity & Metabolism
Xiao LuoMinming Zhang
September 25, 2020

Use of SGLT2 Inhibitors During Ramadan: An Expert Panel Statement

Diabetes Research and Clinical Practice
Mohamed HassaneinSamir Assaad Khalil
September 19, 2020
Open Access

A look to the future in non-alcoholic fatty liver disease: Are GLP-1 analogues or SGLT-2 inhibitors the answer?

Diabetes, Obesity & Metabolism
Rebecca K VincentMarc Evans
September 18, 2020
Open Access

Sodium-glucose cotransporter-2 inhibitor for renal function preservation in patients with type 2 diabetes mellitus: A Korean Diabetes Association and Korean Society of Nephrology consensus statement

Kidney Research and Clinical Practice
Tae Jung OhCommittee of Clinical Practice Guideline, Korean Diabetes Association and Committee of the Cooperative Studies, Korean Socie
September 26, 2020

SGLT2 Inhibitors in Resistant Hypertension: A Sweet Solution

American Journal of Hypertension
Karen C Tran, Swapnil Hiremath
September 16, 2020
Open Access

Development and Internal Validation of a Discrete Event Simulation Model of Diabetic Kidney Disease Using CREDENCE Trial Data

Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders
Michael S WillisCheryl Neslusan
September 15, 2020
Open Access

Type II diabetes mellitus: a review on recent drug based therapeutics

Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie
Santwana PadhiAnindita Behera
September 25, 2020

Dapagliflozin in Patients with Chronic Kidney Disease

The New England Journal of Medicine
Hiddo J L HeerspinkDAPA-CKD Trial Committees and Investigators
September 25, 2020

Working Title: The Nephrological Perspective on SGLT-2 Inhibitors in Type 1 Diabetes

Diabetes Research and Clinical Practice
Pieter GillardPer-Henrik Groop
September 24, 2020

Sodium-glucose Cotransporter 2 Inhibitors- a Drug with Anti-diabetic and Cardioprotective Properties

Journal of Diabetes Investigation
Hung-Yuan Li
September 24, 2020

Evaluation of cardiovascular and renal outcomes with ertugliflozin: what is the VERdict from the VERTIS-CV trial?

Expert Opinion on Pharmacotherapy
Kevin Cowart, Nicholas W Carris

Sign up to follow this feed and discover related papers.

Related Feeds

22q11 Deletion Syndrome

22q11.2 deletion syndrome, also known as DiGeorge syndrome, is a congenital disorder caused as a result of a partial deletion of chromosome 22. Here is the latest research.

Aging & Diabetes

This feed focuses on the role of the aging process on developing diabetes.

Alagille Syndrome

Alagille syndrome is a multi-system genetic disorder that can affect the liver, heart, and other parts of the body. It’s characterization includes heart problems, liver damage, jaundice, and xanthomas. Here is the latest research.


Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.


Aneurysms are outward distensions or bulges that occurs in a weakened wall of blood vessels. Discover the latest research on aneurysms here.


Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.


Anthrax toxin, comprising protective antigen, lethal factor, and oedema factor, is the major virulence factor of Bacillus anthracis, an agent that causes high mortality in humans and animals. Here is the latest research on Anthrax.

Anthrax Vaccines

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.

© 2020 Meta ULC. All rights reserved